Most patients on mirikizumab-mrkz for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years community news Most patients on mirikizumab-mrkz for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years manager 19 February، 2025 18 February 2025: The latest results of VIVID-2 open-label extension study, had come out showing that the... Read More Read more about Most patients on mirikizumab-mrkz for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years
